The Biotech Trader Handbook

The neurotherapy sector is exploding - psychedelics, ketamine, digital therapeutics and breakthrough CNS treatments are moving from fringe science to mainstream medicine. Billions in market cap hang on clinical trial readouts, FDA decisions and mechanism-of-action ("MoA") validation. Most traders lose because they don't understand the science. They chase headlines without knowing whether a 5-HT2A agonist will actually work, or why NMDA antagonist trials fail. They can't distinguish real breakthroughs from biotech vaporware. This book gives you the unfair advantage.

Inside, you'll master:
- MoA-based catalyst prediction: how receptor mechanisms telegraph trial
outcomes
- Neurotherapy trading framework: systematic evaluation of companies and drug
candidates within a trading framework
- Historical pattern validation: real trade examples with P&L attribution across
psychedelic medicine and ketamine sectors
- AI master prompts to put you ahead of the pack (automate MoA, 9-Variable
analysis, catalyst lists, etc.)

This isn't theory. You'll learn to trade neurotherapy companies the way professionals do. The neurotherapy revolution is here. Either you understand the mechanisms driving it, or you don't.